279 related articles for article (PubMed ID: 27908534)
1. Critical review of the role of intravenous immunoglobulins in idiopathic inflammatory myopathies.
Anh-Tu Hoa S; Hudson M
Semin Arthritis Rheum; 2017 Feb; 46(4):488-508. PubMed ID: 27908534
[TBL] [Abstract][Full Text] [Related]
2. Intravenous Immunoglobulin in Idiopathic Inflammatory Myopathies: a Practical Guide for Clinical Use.
Gandiga PC; Ghetie D; Anderson E; Aggrawal R
Curr Rheumatol Rep; 2023 Aug; 25(8):152-168. PubMed ID: 37261663
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy of adding intravenous immunoglobulins as treatment of refractory dysphagia related to myositis: a retrospective analysis.
Giannini M; Fiorella ML; Tampoia M; Girolamo F; Fornaro M; Amati A; Lia A; Abbracciavento L; D'Abbicco D; Iannone F
Rheumatology (Oxford); 2021 Mar; 60(3):1234-1242. PubMed ID: 32911543
[TBL] [Abstract][Full Text] [Related]
4. [Therapeutic strategy in inflammatory myopathies (polymyositis, dermatomyositis, overlap myositis, and immune-mediated necrotizing myopathy)].
Tournadre A
Rev Med Interne; 2014 Jul; 35(7):466-71. PubMed ID: 24144868
[TBL] [Abstract][Full Text] [Related]
5. High dose subcutaneous immunoglobulin for idiopathic inflammatory myopathies and dysimmune peripheral chronic neuropathies treatment: observational study of quality of life and tolerance.
Hachulla E; Benveniste O; Hamidou M; Mouthon L; Schleinitz N; Lozeron P; Léger JM; Vial C; Viala K
Int J Neurosci; 2017 Jun; 127(6):516-523. PubMed ID: 27412148
[TBL] [Abstract][Full Text] [Related]
6. Subcutaneous IgG in immune-mediate diseases: proposed mechanisms of action and literature review.
Danieli MG; Gelardi C; Pedini V; Moretti R; Gabrielli A; Logullo F
Autoimmun Rev; 2014 Dec; 13(12):1182-8. PubMed ID: 25172241
[TBL] [Abstract][Full Text] [Related]
7. Intravenous immunoglobulin therapy in adult patients with polymyositis/dermatomyositis: a systematic literature review.
Wang DX; Shu XM; Tian XL; Chen F; Zu N; Ma L; Wang GC
Clin Rheumatol; 2012 May; 31(5):801-6. PubMed ID: 22274797
[TBL] [Abstract][Full Text] [Related]
8. Updated consensus statement: Intravenous immunoglobulin in the treatment of neuromuscular disorders report of the AANEM ad hoc committee.
Tavee J; Brannagan TH; Lenihan MW; Muppidi S; Kellermeyer L; D Donofrio P;
Muscle Nerve; 2023 Oct; 68(4):356-374. PubMed ID: 37432872
[TBL] [Abstract][Full Text] [Related]
9. IVIg in myasthenia gravis, Lambert Eaton myasthenic syndrome and inflammatory myopathies: current status.
Illa I
J Neurol; 2005 May; 252 Suppl 1():I14-8. PubMed ID: 15959667
[TBL] [Abstract][Full Text] [Related]
10. Real life picture of the use of intravenous immunoglobulins in idiopathic inflammatory myopathies: Results of a multicentric study.
Barsotti S; Cavazzana I; Zanframundo G; Neri R; Taraborelli M; Cioffi E; Cardelli C; Tripoli A; Codullo V; Tincani A; Cavagna L; Franceschini F; Mosca M
Autoimmun Rev; 2021 Mar; 20(3):102757. PubMed ID: 33476815
[TBL] [Abstract][Full Text] [Related]
11. Therapeutic advances in myositis.
Aggarwal R; Oddis CV
Curr Opin Rheumatol; 2012 Nov; 24(6):635-41. PubMed ID: 22955021
[TBL] [Abstract][Full Text] [Related]
12. Assessment of antibody levels to SARS-CoV-2 in patients with idiopathic inflammatory myopathies receiving treatment with intravenous immunoglobulin.
Bae SS; Faure-Kumar E; Ferbas K; Wang J; Shahbazian A; Truong L; Yang H; McMahon M; FitzGerald JD; Charles-Schoeman C
Rheumatol Int; 2023 Sep; 43(9):1629-1636. PubMed ID: 37368037
[TBL] [Abstract][Full Text] [Related]
13. Use of intravenous immunoglobulin therapy for myositis: an audit in South Australian patients.
Foreman C; Russo P; Davies N; Hissaria P; Proudman S; Hughes T; Limaye V
Intern Med J; 2017 Jan; 47(1):112-115. PubMed ID: 28076913
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic approaches in patients with inflammatory myopathies.
Dalakas MC
Semin Neurol; 2003 Jun; 23(2):199-206. PubMed ID: 12894385
[TBL] [Abstract][Full Text] [Related]
15. Limited effects of high-dose intravenous immunoglobulin (IVIG) treatment on molecular expression in muscle tissue of patients with inflammatory myopathies.
Barbasso Helmers S; Dastmalchi M; Alexanderson H; Nennesmo I; Esbjörnsson M; Lindvall B; Lundberg IE
Ann Rheum Dis; 2007 Oct; 66(10):1276-83. PubMed ID: 17277004
[TBL] [Abstract][Full Text] [Related]
16. Clinical applications of immunoglobulin in neuromuscular diseases: focus on inflammatory myopathies.
Souza PV; Pinto WB; Oliveira AS
Arq Neuropsiquiatr; 2014 Dec; 72(12):966-71. PubMed ID: 25465778
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms of action of intravenous immunoglobulin in inflammatory muscle disease.
Quick A; Tandan R
Curr Rheumatol Rep; 2011 Jun; 13(3):192-8. PubMed ID: 21503696
[TBL] [Abstract][Full Text] [Related]
18. Using immunoglobulins in muscular disease treatment.
Pul R; Stangel M
Expert Opin Biol Ther; 2008 Aug; 8(8):1143-50. PubMed ID: 18613765
[TBL] [Abstract][Full Text] [Related]
19. Intravenous gamma globulin as first line therapy in polymyositis and dermatomyositis: an open study in 11 adult patients.
Cherin P; Piette JC; Wechsler B; Bletry O; Ziza JM; Laraki R; Godeau P; Herson S
J Rheumatol; 1994 Jun; 21(6):1092-7. PubMed ID: 7932419
[TBL] [Abstract][Full Text] [Related]
20. Inflammatory myopathies: management of steroid resistance.
Dalakas MC
Curr Opin Neurol; 2011 Oct; 24(5):457-62. PubMed ID: 21799409
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
